Increased expression of the HDAC9 gene is associated with antiestrogen resistance of breast cancers

Estrogens play a pivotal role in breast cancer etiology, and endocrine therapy remains the main first line treatment for estrogen receptor‐alpha (ERα)‐positive breast cancer. ER are transcription factors whose activity is finely regulated by various regulatory complexes, including histone deacetylases (HDACs). Here, we investigated the role of HDAC9 in ERα signaling and response to antiestrogens in breast cancer cells. Various Michigan Cancer Foundation‐7 (MCF7) breast cancer cell lines that overexpress class IIa HDAC9 or that are resistant to the partial antiestrogen 4‐hydroxy‐tamoxifen (OHTam) were used to study phenotypic changes in response to ER ligands by using transcriptomic and gene set enrichment analyses. Kaplan–Meier survival analyses were performed using public transcriptomic datasets from human breast cancer biopsies. In MCF7 breast cancer cells, HDAC9 decreased ERα mRNA and protein expression and inhibited its transcriptional activity. Conversely, HDAC9 mRNA was strongly overexpressed in OHTam‐resistant MCF7 cells and in ERα‐negative breast tumor cell lines. Moreover, HDAC9‐overexpressing cells were less sensitive to OHTam antiproliferative effects compared with parental MCF7 cells. Several genes (including MUC1, SMC3 and S100P) were similarly deregulated in OHTam‐resistant and in HDAC9‐overexpressing MCF7 cells. Finally, HDAC9 expression was positively associated with genes upregulated in endocrine therapy‐resistant breast cancers and high HDAC9 levels were associated with worse prognosis in patients treated with OHTam. These results demonstrate the complex interactions of class IIa HDAC9 with ERα signaling in breast cancer cells and its effect on the response to hormone therapy.

[1]  Ö. Sahin,et al.  Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer , 2018, Clinical Cancer Research.

[2]  R. Gray,et al.  E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer , 2018, npj Breast Cancer.

[3]  P. Balaguer,et al.  Effect of tamoxifen and fulvestrant long-term treatments on ROS production and (pro/anti)-oxidant enzymes mRNA levels in a MCF-7-derived breast cancer cell line , 2016, Breast Cancer.

[4]  H. Cui,et al.  Downregulation of HDAC9 inhibits cell proliferation and tumor formation by inducing cell cycle arrest in retinoblastoma. , 2016, Biochemical and biophysical research communications.

[5]  E. Perez,et al.  Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients. , 2016, Clinical breast cancer.

[6]  B. Radotra,et al.  Overexpression of HDAC9 promotes oral squamous cell carcinoma growth, regulates cell cycle progression, and inhibits apoptosis , 2016, Molecular and Cellular Biochemistry.

[7]  Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors , 2016, Oncotarget.

[8]  M. Parra.  Class IIa HDACs – new insights into their functions in physiology and pathology , 2015, The FEBS journal.

[9]  J. Ji,et al.  CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance , 2014, PloS one.

[10]  Martin Clynes,et al.  BreastMark: An Integrated Approach to Mining Publicly Available Transcriptomic Datasets Relating to Breast Cancer Outcome , 2013, Breast Cancer Research.

[11]  Marketa Zvelebil,et al.  ROCK: a resource for integrative breast cancer data analysis , 2013, Breast Cancer Research and Treatment.

[12]  D. Kufe,et al.  Oncogenic MUC1-C Promotes Tamoxifen Resistance in Human Breast Cancer , 2013, Molecular Cancer Research.

[13]  Wilfried Gouraud,et al.  bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses , 2013, Database J. Biol. Databases Curation.

[14]  E. Martin,et al.  Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration , 2012, Breast Cancer Research.

[15]  Y. Luqmani,et al.  Estrogen Receptor Silencing Induces Epithelial to Mesenchymal Transition in Human Breast Cancer Cells , 2011, PloS one.

[16]  M. Moasser,et al.  A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer , 2011, British Journal of Cancer.

[17]  Shiuan Chen,et al.  SGK3 is an estrogen-inducible kinase promoting estrogen-mediated survival of breast cancer cells. , 2011, Molecular endocrinology.

[18]  A. Ashworth,et al.  Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen , 2011, Proceedings of the National Academy of Sciences.

[19]  L. Zou,et al.  High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy , 2011, Proceedings of the National Academy of Sciences.

[20]  F. Dalenc,et al.  Manipulating Protein Acetylation in Breast Cancer: A Promising Approach in Combination with Hormonal Therapies? , 2010, Journal of biomedicine & biotechnology.

[21]  Kellie J. Archer,et al.  High-throughput assessment of CpG site methylation for distinguishing between HCV-cirrhosis and HCV-associated hepatocellular carcinoma , 2010, Molecular Genetics and Genomics.

[22]  H. Sai,et al.  Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. , 2010, Gastroenterology.

[23]  E. Olson,et al.  Myocyte Enhancer Factor 2 and Class II Histone Deacetylases Control a Gender-Specific Pathway of Cardioprotection Mediated by the Estrogen Receptor , 2010, Circulation research.

[24]  P. Munster,et al.  Histone deacetylase inhibitor induced modulation of anti-estrogen therapy. , 2009, Cancer letters.

[25]  S. Valente,et al.  Specific Activity of Class II Histone Deacetylases in Human Breast Cancer Cells , 2008, Molecular Cancer Research.

[26]  R. Riggins,et al.  Pathways to tamoxifen resistance. , 2007, Cancer letters.

[27]  Margaret Warner,et al.  Estrogen receptors: how do they signal and what are their targets. , 2007, Physiological reviews.

[28]  Ajay N. Jain,et al.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.

[29]  W. Ahn,et al.  Gene expression profiles in squamous cell cervical carcinoma using array-based comparative genomic hybridization analysis , 2006, International Journal of Gynecologic Cancer.

[30]  S. Culine,et al.  Peroxisome Proliferator-Activated Receptor γ Regulates E-Cadherin Expression and Inhibits Growth and Invasion of Prostate Cancer , 2006, Molecular and Cellular Biology.

[31]  A. Nobel,et al.  Concordance among gene-expression-based predictors for breast cancer. , 2006, The New England journal of medicine.

[32]  P. Raynaud,et al.  RCL2, a new fixative, preserves morphology and nucleic acid integrity in paraffin-embedded breast carcinoma and microdissected breast tumor cells. , 2006, The Journal of molecular diagnostics : JMD.

[33]  P. Balaguer,et al.  Transcriptional Regulation of the Human NRIP1/RIP140 Gene by Estrogen Is Modulated by Dioxin Signalling , 2006, Molecular Pharmacology.

[34]  J. Mesirov,et al.  From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005 .

[35]  Yingxuan Chen,et al.  Histone acetylation regulates p21WAF1 expression in human colon cancer cell lines. , 2004, World journal of gastroenterology.

[36]  H. Kawai,et al.  Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor α , 2003, International journal of cancer.

[37]  Lyn Healy,et al.  The Histone Deacetylase 9 Gene Encodes Multiple Protein Isoforms* , 2003, The Journal of Biological Chemistry.

[38]  Chun Li Zhang,et al.  Class II Histone Deacetylases Act as Signal-Responsive Repressors of Cardiac Hypertrophy , 2002, Cell.

[39]  S. Schnittger,et al.  Chromosomal organization and localization of the human histone deacetylase 9 gene (HDAC9). , 2002, Biochemical and biophysical research communications.

[40]  V. Jordan,et al.  The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. , 2002, The Lancet. Oncology.

[41]  Neil J. McKenna,et al.  Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators , 2002, Cell.

[42]  Richard A. Rifkind,et al.  Cloning and characterization of a histone deacetylase, HDAC9 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[43]  E. Olson,et al.  The transcriptional corepressor MITR is a signal-responsive inhibitor of myogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  H. Richard-Foy,et al.  Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling. , 2000, Cancer research.

[45]  F. May,et al.  Selective Promoter Usage of the Human Estrogen Receptor-α Gene and Its Regulation by Estrogen , 1999 .

[46]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[47]  R. Clarke,et al.  MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. , 1993, Cancer research.

[48]  B. Henderson,et al.  Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. , 1988, Cancer research.

[49]  R. Clarke,et al.  Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model , 2017, Journal of the National Cancer Institute.

[50]  A. Nicolas,et al.  HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts , 2014, Breast Cancer Research and Treatment.

[51]  E. Olson,et al.  The many roles of histone deacetylases in development and physiology: implications for disease and therapy , 2009, Nature Reviews Genetics.

[52]  F. May,et al.  Selective promoter usage of the human estrogen receptor-alpha gene and its regulation by estrogen. , 1999, Molecular endocrinology.